drugset

drugset / Trial / NCT00250926

Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia

NCT00250926 ↗

Phase 2 Completed 23 enrolled Dana-Farber Cancer Institute Beth Israel Deaconess Medical Center · collab Millennium Pharmaceuticals, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out if the combination of bortezomib (Velcade), dexamethasone (Decadron) and rituximab (Rituxan) is effective in treating Waldenstrom's macroglobulinemia.

Timeline

Start: 2005-10
Primary completion: 2007-03
Completion: 2009-02

Publications

Results Treon SP, Ioakimidis L, Soumerai JD, Patterson CJ, Sheehy P, Nelson M, Willen M, Matous J, Mattern J 2nd, Diener JG, Keogh GP, Myers TJ, Boral A, Birner A, Esseltine DL, Ghobrial IM. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009 Aug 10;27(23):3830-5. doi: 10.1200/JCO.2008.20.4677. Epub 2009 Jun 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bortezomib	Small molecule	1.3 mg/m2	Intravenous
Subject	Dexamethasone	Small molecule	40 mg	Intravenous
Subject	Rituximab	Monoclonal antibody	375 mg/m2	Intravenous

Indications